From a dataset of over 600 pts w/ HR+MBC BRCA1/BRCA2/PALB2, Gerneiva Parkinson demonstrates 🔑 genomic signatures, immune cell landscape, and demonstrates (from real-world data) no significant diff in sequencing, although with small # #ESMO24 OncoAlert

#KN522 OS data 5 yrs after the initial pCR presentation 75 months of f/u for chemo +/ pembro I stage II and III #TNBC 🌟 EFS is stable from before with 9% improvement w/ pembro 👏 OS improved by 5% (81.7-> 86.6%) #ESMO24 #ESMOAmbassadors

Peter Schmid presents the OS data from KN522 #ESMO24 publl now in NEJM. >6 year FU: 9% EFS benefit, 5% ⬆️OS with pembro pre/post op for TNBC. Pts with PCR had 95% survival +/-pembro but 6% ⬆️OS in nonPCR + pembro. Safety same. Huge advance for TNBC. Need biomarkers! OncoAlert

In lower-income countries, 1 in 15 children with cancer die from treatment-related complications. We can and we must change that. A simple tool has shown great success in catching these complications early, and we're working to make it sustainable. go.nih.gov/Ui1mfNh #CCAM

2023 Snapshot: State of the Oncology Workforce in America | JCO Oncology Practice ASCO OncoAlert Important information about the who will take care of the rising number of patients with cancer diagnosis ascopubs.org/doi/pdf/10.120…

📌Now 🔛 an expert panel of clinicians talk through how they handle challenging clinical decisions! Clinical case discussions by Erika Hamilton, MD, FASCO Icro Meattini Tari King MD Sonya Reid, MD MPH Harold Burstein, Anne Vincent-Salomon moderator: Debra Patt #SABCS24 #day2 OncoAlert #OncoAlertAF

2024 proving a big year for palbociclib in MBC - Inavolisib approval with palbo - PATINA Otto Metzger shows major benefit in maintenance phase of ER+ HER2+ - Flatiron data show identical survival for all 3 CDK46i's in US population

PATINA study of induction THP > maintenance HP + ET +/- palbo in ER+HER2+ MBC. Takeaway: after 6 cycles induction THP, patients can expect nearly 4 years of maintenance HP/ET/palbo on avg before re-needing chemo/ADC!

Dr. Krop emphasizes we don't have the data in #bcsm that the GI literature does for MRD. 🛑 Shouldn't order tests (outside of a clinical trial) without clear actions to take based on results. ❓Will outcomes be changed in ctDNA+? Unsure. #SABCS24 SABCS OncoAlert

8.5% improvement in pCR with pembrolizumab in ER+ early #BreastCancer published this week! #bcsm Nature Medicine Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial | Nature Medicine

DB-06 #TDXD approved for HER-2 "ultra low" (IHC but staining) breast cancer, and also in the 1st line setting, moving opportunity for #TDXd up. #bcsm OncoAlert astrazeneca.com/media-centre/p…

Looking forward to co-chairing an exciting Rapid Oral Abstract Session in Metastatic Breast Cancer. 📣Join us today at 2:45 CT in Hall D2 ASCO OncoAlert #bcsm #ASCO25

#ASCENT04 showing sacituzumab + pembro better for 1L PDL1+ TNBC than chemo + pembro PFS: 7.8 vs. 11.2 mo, HR 0.65 ORR higher and more durable w/ SG Fewer discontinuations and reductions w/ SG #ASCO25 #bcsm 🎶 "movin' on up" 🎶 Sara Tolaney

Dr Sonya Reid makes excellent point in Metastatic TNBC Sadly 50% of patients do not make it to second line therapy in mTNBC. In that case, waiting beyond first line to give a more effective regimen seems silly. #bcsm #ASCO25

ASCENT-04 met TNBC evaluating use of sacituzumab +pembro vs chemo + pembro in the 1st line ➡️ baseline 50% lung 25% liver mets ➡️ 11.2 mo vs 7.8 mo imp in mPFS ➡️ Longer DOR 16.5 mo vs 9.2 mo and higher ORR ➡️ no inc irAE New potential SOC! #ASCO25 Sara Tolaney

Great discussion by Sonya Reid, MD MPH! #ASCO25 #bcsm

Excellent discussion by Sonya Reid, MD MPH A perfect close to a great oral session 🤩 #ASCO25 #bcsm

Komen grantee @sonyareid07 discussed meaningful advances in metastatic breast cancer at #ASCO25 - new data shows we're moving toward more effective and convenient options for patients, including oral chemo and biomarker-guided therapies.

I think that's probably correct. In 2nd line, SC > chemo. By the additive property, we now see that SG + pembro > chemo + pembro. Control arm performed as in KN355 chemo/pembro. Seems like a good option, and supports growing idea that SG might be preferred in TNBC.

#SOFT and #TEXT looking at AI vs. tam and OFS vs. not, 15 yr f/u 📌Adding OFS gives you 3.7% ⬆️ DFS 📌OFS + AI gets you 6.5% ⬆️ DFS 📍OFS + AI improves gives you ⬆️ 4.3% OS 🌟 Ultra young <35, it's even more important #ASCO25 #bcsm